Our study suggests that postoperative RT is associated with improved survival in most DCIS patients. The nomograms showed good performance in predicting the DSS and DFS of DCIS patients, and our online tool well visualized the DSS and DFS prediction to support clinical decision-making.
In conclusion, the present investigation reveals a noteworthy correlation between elevated levels of MRP2 protein in CTCs and TNBC. This finding deepens our understanding of the molecular mechanisms that contribute to the metastasis of breast cancer and provides a scientific basis for predicting treatment outcomes in breast cancer patients exhibiting elevated levels of MRP2 protein expression.
4 days ago
Observational data • Retrospective data • Journal • Circulating tumor cells
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
In HER2-low breast cancer, TLSs were associated with higher histological grade, the presence of DCIS, absence of lymphovascular invasion, as well as expression of ER negative, PR negative, HER2 2 + , high K-i67, and triple-negative breast cancer. Additionally, the clinical prognosis value of TLSs (such as DFS) exhibited a correlation with the patient's age.
P=N/A, N=130, Recruiting, Jewish General Hospital | Trial completion date: Jun 2023 --> Dec 2027 | Trial primary completion date: Jun 2022 --> Dec 2027
7 days ago
Trial completion date • Trial primary completion date • Liquid biopsy
These findings suggest that the anti-breast cancer effect of DOT1L inhibition is mediated by multiple mechanisms, including activation of innate immune signaling.
8 days ago
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • STING (stimulator of interferon response cGAMP interactor 1) • DOT1L (DOT1 Like Histone Lysine Methyltransferase)
|
HER-2 positive • ER positive • HER-2 negative • HER-2 expression • ER negative • ER positive + HER-2 negative • HER-2 negative + ER positive
Remarkably, the LCOR-ERα disruption converts HR+BC immune-cold tumors into immune-hot tumors responsive to ICB by increased antigen presentation machinery (APM) expression, immune infiltration, T cell recognition and mediated killing. In conclusion, ERα inhibition and the disruption of LCOR to ERα represent a novel therapeutic strategy and an opportunity to elicit immunotherapeutic benefit in HR+BC patients.
We confirmed that these organoids are unresponsive to estrogen, can self-renew, and express the stem/progenitor marker CD44. In addition, we observed that these organoids contain outgrowths that resemble the mature ductal and lobular units of the mammary gland, thus making it a suitable model system to study how cancer develops in ER/PR/HER2-negative mammary cells that carry a BRCA1 germline mutation.
11 days ago
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • CD44 (CD44 Molecule)
These findings advance our understanding of genetic susceptibility to different cancers. Future work in larger, more diverse GWAS, coupled with more comprehensive annotation atlases, is essential to expand upon and validate our results.
Subset of AI mice had long-term sustained release tamoxifen placed subscapular on day 8 postpartum...Early metabolic phenotypes in AI and GI glands may be caused by differences in adipocyte repopulation related to estrogen signaling. Long-term metabolic effects of AI lead to similar metabolic effects found in breast cancer.
Despite similar clinicopathological features, IHC2+/ISH- status was independently associated with lower pCR rates compared to IHC1+. These findings suggest that HER2-low subgroups may influence response to NACT and should be considered in multivariable prediction models, potentially informing stratified treatment approaches in the era of anti-HER2 ADCs.
SyMRI-derived quantitative metrics are associated with both pathological and imaging features. Effect size analysis highlights histological grade as the most influential confounding factor in the interpretation of quantitative SyMRI.